Plain-English translation of NCT05588388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether — a medication that stops tumors from building new blood vessels — works better when combined with two other drugs (chemotherapy and an immunotherapy drug called atezolizumab) to treat advanced small-cell lung cancer that has spread to the liver. After the initial treatment phase, participants continue taking the two maintenance medications for up to a year. The goal is to see if this combination helps people with this serious type of cancer live longer and feel better.
Advanced small-cell lung cancer that has spread to the liver is very hard to treat, and doctors need better options for patients who haven't received prior treatment. This trial exists to find out whether adding the medication to traditional chemotherapy and immunotherapy can improve outcomes for people facing this diagnosis.
You likely qualify if…
You likely don't qualify if…
You would receive four medications given as intravenous infusions every three weeks during the initial treatment phase. After that, if the cancer responds well, you would continue receiving two of the medications (the maintenance phase) for up to one year or until the cancer progresses or side effects become unacceptable. You would need regular visits for infusions, blood tests, and imaging scans to monitor how the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States